Valuation: Forte Biosciences, Inc.

Market Cap 1.34B 1.18B 1.09B 1B 1.89B 129B 1.91B 12.98B 5.07B 63.38B 5.03B 4.92B 219B P/E 2026 *
-13.3x
P/E 2027 * -12.9x
Enterprise Value 1.34B 1.18B 1.09B 1B 1.89B 129B 1.91B 12.98B 5.07B 63.38B 5.03B 4.92B 219B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day-8.24%
1 week+12.12%
Current month+157.79%
1 month+195.47%
3 months+99.56%
6 months+71.72%
Current year+100.88%
1 week 47.35
Extreme 47.35
62.46
1 month 18.4
Extreme 18.405
62.46
Current year 15.51
Extreme 15.51
62.46
1 year 9.1
Extreme 9.1
62.46
3 years 4.11
Extreme 4.11
62.46
5 years 4.11
Extreme 4.11
812.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Chief Financial Officer

884 0.0043%
1/7/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
16/6/26 Free

Chief Financial Officer

22,000 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
-8.24%+12.12%+409.58%+116.95% 1.34B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.76%+2.36%+77.51%+165.55% 24.14B
Weighted average by Cap. -0.91%+2.15%+43.22%+135.58%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.91M -78.04M -71.61M -135M -9.2B -137M -927M -362M -4.52B -359M -351M -15.64B -130M -115M -107M -97.76M -184M -12.56B -187M -1.27B -494M -6.18B -490M -479M -21.35B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
24/07/26 US$54.78 -8.24% 575,893
23/07/26 US$59.70 +5.42% 752,162
22/07/26 US$56.63 +11.63% 530,808
21/07/26 US$50.73 +6.82% 927,508
20/07/26 US$47.49 -2.80% 602,259
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
54.78USD
Average target price
66.60USD
Spread / Average Target
+21.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock